FIELD: medicine. SUBSTANCE: method involves concurrently acting upon fibrinolysis, reducing blood platelets aggregation and increasing injured eye tissue antioxidation protection. To do it, autoplasma supernatant is administered in parabulbar and parenteral mode. Supernatant is produced as a result of irreversible blood platelets aggregation with concurrent application of adenosine triphosphate in the amount of 0.3-0.4 mg/ml and thrombin in the amount of 0.1-0.3 ED/ml. EFFECT: enhanced effectiveness of treatment. 4 cl, 3 tbl
Authors
Dates
2000-12-27—Published
1998-09-23—Filed